Important Note Before Reading

The ratings and target prices below reproduce the supplied brokerage summary and have not all been independently verified against the original research reports. Price targets are estimates, not guaranteed future prices. Check the publication date, current share price and latest brokerage report before making investment decisions.

• JPMorgan: Overweight | Target ₹310
• HSBC: Buy — Upgrade | Target ₹284
• UBS: Buy | Target ₹300
• Jefferies: Hold | Target ₹275
• Citi: Buy | Target ₹310

What to note: The supplied summary shows predominantly positive ratings, with Jefferies taking a more cautious Hold position. Investors should examine asset quality, credit growth, deposit costs and provisions before drawing conclusions.

• JPMorgan: Overweight | Target ₹590
• Jefferies: Buy | Target ₹470
• Kotak: Buy | Fair value ₹550
• Citi: Buy | Target ₹545

What to note: The supplied targets vary significantly. Investors should monitor shipment growth, operating margins, competitive intensity and the company's path towards sustainable profitability.

• HSBC: Buy | Target ₹2,050
• Bank of America (BofA): Underperform | Target ₹1,850
• Kotak Neo: Add | Target ₹2,060

What to note: The ratings indicate differing views on valuation and future performance. Investors should review product pipelines, regulatory developments, specialty medicines and earnings expectations.

• Jefferies: Buy | Target ₹1,540
• HSBC: Hold | Target ₹1,100
• Bernstein: Outperform | Target ₹1,085

What to note: The large gap between the reported Jefferies target and the other two targets highlights differing valuation assumptions. Investors should assess insurance distribution economics, regulatory risks, customer acquisition costs and profitability.

• HSBC: Buy | Target ₹540
• Goldman Sachs: Buy | Target ₹520
• Jefferies: Buy | Target ₹530

What to note: The supplied targets are relatively close to one another. Investors should monitor volume growth, distribution expansion, input costs, weather conditions and demand trends in the company's markets.

• JPMorgan: Overweight | Target ₹1,675
• Jefferies: Buy | Target ₹1,710

What to note: Investors should evaluate Reliance's energy, retail, telecom and new-energy businesses separately, as each segment has different growth drivers, margins and capital requirements.

• Jefferies: Buy | Target ₹10,540
• Kotak: Sell | Fair value ₹5,990

What to note: The substantial difference between these reported valuations makes this one of the most important disagreements in the list. Investors should examine earnings assumptions, specialty-chemical demand, capacity utilisation and valuation multiples before forming a view.

• Citi: Buy | Target ₹200
• Jefferies: Hold | Target ₹185

What to note: Natural gas transmission volumes, gas marketing margins, pipeline investments and changes in energy demand are important factors to monitor.

• Kotak: Upgrade to Buy | Fair value ₹14,900
• Jefferies: Hold | Target ₹12,765

What to note: Investors should assess manufacturing growth, customer concentration, margins, execution and valuation. The reported upgrade does not eliminate the risks associated with a high-growth manufacturing business.

• JPMorgan: Initiated coverage with Overweight | Target ₹2,130

What to note: Exchange-related businesses can benefit from market participation and transaction activity, but investors must also consider regulatory changes, market structure, competition and the company's listing or trading status when relevant.

• Jefferies: Hold | Target ₹2,700

What to note: Gold-loan growth, loan yields, competition, credit costs and gold-price movements can affect performance. Confirm the latest recommendation and target before relying on this figure.

• Jefferies: Hold | Target ₹1,315

What to note: Demat-account growth, investor participation, market activity, transaction volumes and valuation are relevant factors for evaluating a depository business.

• Jefferies: Buy | Target ₹2,250

What to note: Retail consumption, mall occupancy, rental income, footfall, leasing spreads and planned capital expenditure can influence the company's performance.

• Kotak: Sell | Fair value ₹1,120

What to note: Investors should examine order visibility, capacity utilisation, margins, customer demand and valuation assumptions. A Sell rating is a brokerage opinion, not a certainty about future share-price performance.

• Kotak: Add | Fair value ₹1,690

What to note: Chemical demand, realisations, raw-material costs, operating margins and capacity expansion are important variables when assessing the company's earnings outlook.

Investor Takeaway

Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, observes that brokerage recommendations are most useful when investors understand the reasoning behind each rating. A Buy recommendation does not automatically make a stock attractive at every price, while a Hold or Sell rating does not guarantee that a stock will decline.

Investors should compare the latest research report with current valuation, earnings growth, balance-sheet quality, business risks and their own investment horizon. The largest differences between brokerage targets may be especially useful starting points for further research.

1. What are brokerage ratings?
Brokerage ratings express an analyst's opinion about a stock's expected performance or investment attractiveness over a stated period.

2. What does a Buy rating mean?
A Buy rating generally indicates that an analyst expects the stock to perform favourably under the assumptions in the research report. It is not a guarantee of returns.

3. What is a price target?
A price target is an analyst's estimated share price for a specified future period, often around 12 months. The actual outcome can differ significantly.

4. Why do brokerages give different targets for the same stock?
Analysts may use different earnings forecasts, valuation multiples, growth assumptions, risk estimates and time horizons.

5. Should investors buy a stock immediately after an upgrade?
Not automatically. Check the current price, valuation, the reason for the upgrade and whether the research report's assumptions remain valid.

6. Are the targets in this article guaranteed?
No. They are reported estimates supplied for this summary and should be verified against original research reports. Actual share prices can rise or fall substantially.